Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are women and above a certain age (confirm with trial site for the specific age requirement)
- People who have been diagnosed with early-stage breast cancer
- People who have had a CT scan within the last 3 months that includes a specific area of the body at the lower back level (called L3)
- People for whom a doctor has recommended a chemotherapy drug called docetaxel at a dose of 100 mg/m² as a treatment after surgery
Who may not be able to join:
- People whose breast cancer is classified as HER2-positive or triple negative (specific tumour types based on lab testing)
- People who are pregnant or currently breastfeeding
- People who are under a legal guardianship or curatorship arrangement
- People who are currently receiving another chemotherapy drug or targeted cancer therapy at the same time
- People who have a diagnosed psychosocial disorder
- People who have received another chemotherapy drug or targeted cancer therapy within the 20 days before a required blood sample is taken
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Florian Clatot, Prof, Centre Henri Becquerel
Phone: +33232082231
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of docetaxel area under courb between obese and lean patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.